Publication | Open Access

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Breast OncologyMedicinePathologyNeoadjuvant TreatmentAnthracycline-based ChemotherapyBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular OncologyHer2-positive Breast Cancer